Each year, an estimated 300,000 adults in the United States die of causes related to obesity [2] According to the guidelines of the National Institute of Health (NIH) regarding the treatment of obesity, weight loss drugs approved by the FDA [US Food and Drug Administration] may only be used as part of a comprehensive weight loss program, including dietary therapy and physical activity, for patients with a BMI [body mass index] of 30 with no concomitant obesity-related risk factors or diseases, and for patients with a BMI of 27 with concomitant obesity-related risk factors or diseases[3].The risk factors and diseases considered important enough to warrant pharmacotherapy at a BMI of 27--29.9 are hypertension, dyslipidemia, coronary heart disease (CHD), type 2 diabetes, and sleep apnea [3]
This creates unexpected financial stress during critical construction phases
Some important targets of estrogen include the LDL receptor, progesterone receptor, IGF-1, MYC, and many more
Originally derived from a body protection compound (BPC) found in the stomach, this synthetic peptide is known for its regenerative properties and potential benefits in wound healing, muscle recovery, and digestive health
No, there are currently no large-scale, double-blind, placebo-controlled human clinical trials specifically for BPC 157 and sciatica
Somatostatin noncompetitively inhibits GH and other hormone secretion
